Eitan Kerem1, Michael W Konstan2, Kris De Boeck3, Frank J Accurso4, Isabelle Sermet-Gaudelus5, Michael Wilschanski1, J Stuart Elborn6, Paola Melotti7, Inez Bronsveld8, Isabelle Fajac9, Anne Malfroot10, Daniel B Rosenbluth11, Patricia A Walker12, Susanna A McColley13, Christiane Knoop14, Serena Quattrucci15, Ernst Rietschel16, Pamela L Zeitlin17, Jay Barth18, Gary L Elfring18, Ellen M Welch18, Arthur Branstrom18, Robert J Spiegel18, Stuart W Peltz18, Temitayo Ajayi18, Steven M Rowe19. 1. Center for Cystic Fibrosis, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 2. Rainbow Babies & Children's Hospital and Case Western Reserve University, Cleveland, OH, USA. Electronic address: michael.konstan@case.edu. 3. University Hospitals Leuven/Catholic University of Leuven, Leuven, Belgium. 4. Children's Hospital Colorado, Aurora, CO, USA. 5. Centre de Ressource et de Competence de la Mucoviscidose, Service de Pediatrie Generale, Service de Pneumologie Pediatrique, Service de Radiologie Pediatrique, Centre d'Investigation Clinique Hôpital Necker-Enfants Malades, Paris, France. 6. Centre for Infection and Immunity, Queen's University, Belfast, Northern Ireland, UK. 7. Centro Regionale Veneto di Ricerca, Prevenzione e Cura Fibrosi Cistica, Azienda Ospedaliera di Verona, Verona, Italy. 8. Department of Pulmonology, University Medical Centre Utrecht, Utrecht, Netherlands. 9. Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Physiology, Hôpital Cochin, AP-HP, Paris, France. 10. Cystic Fibrosis Clinic, Universitair Ziekenhuis Brussel/Vrije Universiteit Brussel, Brussels, Belgium. 11. Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, MO, USA. 12. Pulmonary Medicine, Mount Sinai Hospital, New York, NY, USA. 13. Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 14. Department of Chest Medicine, Hôpital Universitaire Erasme, Brussels, Belgium. 15. Regional Cystic Fibrosis Centre, Paediatrics and Infant Neuropsychiatry Department, 'Sapienza' University of Rome, Rome, Italy. 16. Cystic Fibrosis Centre, Children's Hospital University of Cologne, Cologne, Germany. 17. Pediatric Pulmonology, Johns Hopkins Pediatric Specialty Clinic, Rubenstein Child Health, Baltimore, MD, USA. 18. PTC Therapeutics, South Plainfield, NJ, USA. 19. Translational Research Unit, Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract
BACKGROUND: Ataluren was developed to restore functional protein production in genetic disorders caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients. This trial was designed to assess the efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis. METHODS: This randomised, double-blind, placebo-controlled, phase 3 study enrolled patients from 36 sites in 11 countries in North America and Europe. Eligible patients with nonsense-mutation cystic fibrosis (aged ≥ 6 years; abnormal nasal potential difference; sweat chloride >40 mmol/L; forced expiratory volume in 1 s [FEV1] ≥ 40% and ≤ 90%) were randomly assigned by interactive response technology to receive oral ataluren (10 mg/kg in morning, 10 mg/kg midday, and 20 mg/kg in evening) or matching placebo for 48 weeks. Randomisation used a block size of four, stratified by age, chronic inhaled antibiotic use, and percent-predicted FEV1. The primary endpoint was relative change in percent-predicted FEV1 from baseline to week 48, analysed in all patients with a post-baseline spirometry measurement. This study is registered with ClinicalTrials.gov, number NCT00803205. FINDINGS:Between Sept 8, 2009, and Nov 30, 2010, 238 patients were randomly assigned, of whom 116 in each treatment group had a valid post-baseline spirometry measurement. Relative change from baseline in percent-predicted FEV1 did not differ significantly between ataluren and placebo at week 48 (-2.5% vs -5.5%; difference 3.0% [95% CI -0.8 to 6.3]; p=0.12). The number of pulmonary exacerbations did not differ significantly between treatment groups (rate ratio 0.77 [95% CI 0.57-1.05]; p=0.0992). However, post-hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a 5.7% difference (95% CI 1.5-10.1) in relative change from baseline in percent-predicted FEV1 between the ataluren and placebo groups at week 48 (-0.7% [-4.0 to 2.1] vs -6.4% [-9.8 to -3.7]; nominal p=0.0082), and fewer pulmonary exacerbations in the ataluern group (1.42 events [0.9-1.9] vs 2.18 events [1.6-2.7]; rate ratio 0.60 [0.42-0.86]; nominal p=0.0061). Safety profiles were generally similar for ataluren and placebo, except for the occurrence of increased creatinine concentrations (ie, acute kidney injury), which occurred in 18 (15%) of 118 patients in the ataluren group compared with one (<1%) of 120 patients in the placebo group. No life-threatening adverse events or deaths were reported in either group. INTERPRETATION: Although ataluren did not improve lung function in the overall population of nonsense-mutation cystic fibrosis patients who received this treatment, it might be beneficial for patients not taking chronic inhaled tobramycin. FUNDING: PTC Therapeutics, Cystic Fibrosis Foundation, US Food and Drug Administration's Office of Orphan Products Development, and the National Institutes of Health.
RCT Entities:
BACKGROUND:Ataluren was developed to restore functional protein production in genetic disorders caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients. This trial was designed to assess the efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis. METHODS: This randomised, double-blind, placebo-controlled, phase 3 study enrolled patients from 36 sites in 11 countries in North America and Europe. Eligible patients with nonsense-mutation cystic fibrosis (aged ≥ 6 years; abnormal nasal potential difference; sweat chloride >40 mmol/L; forced expiratory volume in 1 s [FEV1] ≥ 40% and ≤ 90%) were randomly assigned by interactive response technology to receive oral ataluren (10 mg/kg in morning, 10 mg/kg midday, and 20 mg/kg in evening) or matching placebo for 48 weeks. Randomisation used a block size of four, stratified by age, chronic inhaled antibiotic use, and percent-predicted FEV1. The primary endpoint was relative change in percent-predicted FEV1 from baseline to week 48, analysed in all patients with a post-baseline spirometry measurement. This study is registered with ClinicalTrials.gov, number NCT00803205. FINDINGS: Between Sept 8, 2009, and Nov 30, 2010, 238 patients were randomly assigned, of whom 116 in each treatment group had a valid post-baseline spirometry measurement. Relative change from baseline in percent-predicted FEV1 did not differ significantly between ataluren and placebo at week 48 (-2.5% vs -5.5%; difference 3.0% [95% CI -0.8 to 6.3]; p=0.12). The number of pulmonary exacerbations did not differ significantly between treatment groups (rate ratio 0.77 [95% CI 0.57-1.05]; p=0.0992). However, post-hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a 5.7% difference (95% CI 1.5-10.1) in relative change from baseline in percent-predicted FEV1 between the ataluren and placebo groups at week 48 (-0.7% [-4.0 to 2.1] vs -6.4% [-9.8 to -3.7]; nominal p=0.0082), and fewer pulmonary exacerbations in the ataluern group (1.42 events [0.9-1.9] vs 2.18 events [1.6-2.7]; rate ratio 0.60 [0.42-0.86]; nominal p=0.0061). Safety profiles were generally similar for ataluren and placebo, except for the occurrence of increased creatinine concentrations (ie, acute kidney injury), which occurred in 18 (15%) of 118 patients in the ataluren group compared with one (<1%) of 120 patients in the placebo group. No life-threatening adverse events or deaths were reported in either group. INTERPRETATION: Although ataluren did not improve lung function in the overall population of nonsense-mutation cystic fibrosispatients who received this treatment, it might be beneficial for patients not taking chronic inhaled tobramycin. FUNDING: PTC Therapeutics, Cystic Fibrosis Foundation, US Food and Drug Administration's Office of Orphan Products Development, and the National Institutes of Health.
Authors: Isabelle Sermet-Gaudelus; Kris De Boeck; Georges J Casimir; François Vermeulen; Teresinha Leal; Agnès Mogenet; Delphine Roussel; Janine Fritsch; Laurence Hanssens; Samit Hirawat; Nilsen L Miller; Scott Constantine; Allen Reha; Temitayo Ajayi; Gary L Elfring; Langdon L Miller Journal: Am J Respir Crit Care Med Date: 2010-07-09 Impact factor: 21.405
Authors: J P Clancy; Z Bebök; F Ruiz; C King; J Jones; L Walker; H Greer; J Hong; L Wing; M Macaluso; R Lyrene; E J Sorscher; D M Bedwell Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: T Shoshani; A Augarten; E Gazit; N Bashan; Y Yahav; Y Rivlin; A Tal; H Seret; L Yaar; E Kerem Journal: Am J Hum Genet Date: 1992-01 Impact factor: 11.025
Authors: Venkateshwar Mutyam; Ming Du; Xiaojiao Xue; Kim M Keeling; E Lucile White; J Robert Bostwick; Lynn Rasmussen; Bo Liu; Marina Mazur; Jeong S Hong; Emily Falk Libby; Feng Liang; Haibo Shang; Martin Mense; Mark J Suto; David M Bedwell; Steven M Rowe Journal: Am J Respir Crit Care Med Date: 2016-11-01 Impact factor: 21.405
Authors: Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2017-04-15 Impact factor: 21.405